ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Loxo Oncology, which is owned by Eli Lilly and Company, is partnering with Kumquat Biosciences to develop small-molecule immunotherapies. Lilly will pay Kumquat $70 million up front, with up to $2 billion in milestone payments. Kumquat will use its small-molecule-developing technology to identify potential antitumor candidates, and Lilly will further develop what it deems the most promising.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter